πŸ’ŠPharmaconomics
← Calendar
Ticker

GOSS

Gossamer Bio, Inc.

7 catalysts on file

GOSS
Gossamer Bio, Inc.
Phase 2 AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
179d ago Feb 23, 2026
SEC 8-K verified 2mo ago
Countdown card β†’
GOSS
Gossamer Bio, Inc.
AdCom AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
67d ago Jun 15, 2026
SEC 8-K verified 2mo ago
Countdown card β†’
GOSS
Gossamer Bio, Inc.
PDUFA AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
T-minus 192 days Mar 1, 2027
SEC 8-K verified 2mo ago
Countdown card β†’
GOSS
Gossamer Bio, Inc.
Approval AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
T-minus 192 days Mar 1, 2027
SEC 8-K verified 2mo ago
Countdown card β†’
GOSS
Gossamer Bio, Inc.
CRL AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Date TBD Date TBD
SEC 8-K verified 2mo ago
Countdown card β†’
GOSS
Gossamer Bio, Inc.
Phase 1 AI-extracted
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Date TBD Date TBD
SEC 8-K verified 2mo ago
Countdown card β†’